FDA's Long-Term Vision For REMS Includes "Plug-And-Play" Standardization
This article was originally published in The Pink Sheet Daily
Executive Summary
OND Director Jenkins notes that risk management plans should be interoperable, but will not be identical.
You may also be interested in...
The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision
FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.
The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision
FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.
REMS And Benefits? FDA, Industry Debate Moving Beyond Safety Information
Included in FDA's upcoming look at improving Risk Evaluation and Mitigation Strategies may be an adjustment to Medication Guides to include drug benefits alongside risks